NASDAQ:FGEN FibroGen (FGEN) Stock Forecast, Price & News $0.97 +0.01 (+1.04%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$0.90▼$1.0050-Day Range$0.79▼$2.2252-Week Range$0.70▼$25.69Volume4.62 million shsAverage Volume6.29 million shsMarket Capitalization$95.42 millionP/E RatioN/ADividend YieldN/APrice Target$22.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability FibroGen MarketRank™ ForecastAnalyst RatingReduce1.67 Rating ScoreUpside/Downside2,164.3% Upside$22.00 Price TargetShort InterestBearish11.96% of Float Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$16,524 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.47) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.18 out of 5 starsMedical Sector442nd out of 970 stocksPharmaceutical Preparations Industry196th out of 455 stocks 2.8 Analyst's Opinion Consensus RatingFibroGen has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no buy ratings, 4 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.00, FibroGen has a forecasted upside of 2,164.3% from its current price of $0.97.Amount of Analyst CoverageFibroGen has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.96% of the float of FibroGen has been sold short.Short Interest Ratio / Days to CoverFibroGen has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in FibroGen has recently increased by 0.46%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldFibroGen does not currently pay a dividend.Dividend GrowthFibroGen does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreFibroGen has received a 74.19% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for the autoimmune system", "Clinical research services for cancer", and "Clinical research services for deficiency diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for FibroGen is -0.84. Previous Next 2.9 News and Social Media Coverage News SentimentFibroGen has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for FibroGen this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for FGEN on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows6 people have added FibroGen to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, FibroGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,524.00 in company stock.Percentage Held by InsidersOnly 2.39% of the stock of FibroGen is held by insiders.Percentage Held by Institutions78.34% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for FibroGen are expected to grow in the coming year, from ($2.47) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of FibroGen is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of FibroGen is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About FibroGen (NASDAQ:FGEN) StockFibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Read More FGEN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FGEN Stock News HeadlinesAugust 30, 2023 | markets.businessinsider.comFibroGen's Pamrevlumab Doesn't Meet Goals In Phase III LELANTOS-2 Trial; Stock Down In Pre-marketAugust 30, 2023 | markets.businessinsider.comThree In A Row: FibroGen's Investigational Drug Flunks In Another Study For Rare Disease In Young BoysSeptember 29, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 30, 2023 | proactiveinvestors.comFibroGen stock plummets as muscular dystrophy drug trial failsAugust 30, 2023 | msn.comFibroGen (NASDAQ: FGEN) Tumbles after Setback in Phase 3 DMD TrialAugust 29, 2023 | marketwatch.comStocks to Watch: FibroGen, BoxAugust 29, 2023 | finance.yahoo.comFibroGen's drug misses mark on yet another clinical trialAugust 29, 2023 | marketwatch.comFibroGen Shares Sink 16% on Pamrevlumab Study Not Meeting Primary EndpointSeptember 29, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 29, 2023 | msn.comFibroGen stock tumbles on failed Phase 3 study for muscular dystrophy drugAugust 29, 2023 | finance.yahoo.comFibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular DystrophyAugust 16, 2023 | finance.yahoo.comDown -46.88% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a TurnaroundAugust 9, 2023 | finance.yahoo.comIs There An Opportunity With FibroGen, Inc.'s (NASDAQ:FGEN) 42% Undervaluation?August 9, 2023 | finance.yahoo.comFibroGen Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 | msn.comB of A Securities Downgrades FibroGen (FGEN)August 8, 2023 | markets.businessinsider.comExpert Ratings for FibroGenAugust 8, 2023 | seekingalpha.comFibroGen Q2 2023 Earnings PreviewAugust 8, 2023 | finance.yahoo.comFibroGen (FGEN) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesAugust 8, 2023 | finance.yahoo.comFibroGen, Inc. (NASDAQ:FGEN) Q2 2023 Earnings Call TranscriptJuly 31, 2023 | bizjournals.comSan FranciscoBusiness TimesJuly 25, 2023 | finance.yahoo.comFibroGen CEO resigns after back-to-back drug study failures, job cutsJuly 25, 2023 | finanznachrichten.deFibroGen, Inc.: FibroGen Announces Leadership TransitionJuly 25, 2023 | finance.yahoo.comFibroGen Announces Leadership TransitionJuly 24, 2023 | finance.yahoo.comFibroGen to Report Second Quarter 2023 Financial ResultsJuly 20, 2023 | msn.comSF biotech company FibroGen laying off nearly a third of its workersJuly 19, 2023 | bizjournals.comPioneering Mission Bay biotech company Fibrogen to cut more than 100 jobsJuly 14, 2023 | finance.yahoo.comFibroGen (FGEN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?See More Headlines Receive FGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter. Email Address FGEN Company Calendar Last Earnings8/07/2023Today9/29/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FGEN CUSIPN/A CIK921299 Webwww.fibrogen.com Phone(415) 978-1200Fax415-978-1902Employees592Year FoundedN/APrice Target and Rating Average Stock Price Forecast$22.00 High Stock Price Forecast$35.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+2,164.3%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-293,650,000.00 Net Margins-246.75% Pretax Margin-248.26% Return on Equity-879.75% Return on Assets-52.38% Debt Debt-to-Equity RatioN/A Current Ratio2.12 Quick Ratio1.91 Sales & Book Value Annual Sales$140.73 million Price / Sales0.68 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-48.58Miscellaneous Outstanding Shares98,210,000Free Float95,863,000Market Cap$95.42 million OptionableOptionable Beta0.55 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Thane Wettig (Age 58)Interim Chief Exec. Officer Comp: $807.35kMr. Juan Graham (Age 46)Sr. VP & CFO Comp: $991.76kDr. Elias Kouchakji (Age 67)Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance Ms. Christine L. Chung (Age 55)Sr. VP of China Operations Comp: $1.27MDr. Barry A. Berkowitz Ph.D.FounderDr. John J. Hunter Ph.D. (Age 60)Chief Scientific Officer Ms. Karen L. BergmanVP of Investor Relations & Corp. CommunicationsMr. Michael D. Lowenstein J.D.Ph.D., Chief Legal OfficerMs. Tricia StewartChief People OfficerMr. Kirk A. Christoffersen MBA (Age 54)Chief Bus. Officer More ExecutivesKey CompetitorsLifeVantageNASDAQ:LFVNAnnovis BioNYSE:ANVSIO BiotechNASDAQ:IOBTOcuphire PharmaNASDAQ:OCUPNGM BiopharmaceuticalsNASDAQ:NGMView All CompetitorsInsiders & InstitutionsJeffrey William HendersonSold 2,000 sharesTotal: $2,060.00 ($1.03/share)Affinity Asset Advisors LLCBought 983,300 shares on 8/21/2023Ownership: 0.000%GTS Securities LLCBought 202,552 shares on 8/16/2023Ownership: 0.206%Wells Fargo & Company MNBought 31,031 shares on 8/15/2023Ownership: 0.124%Stifel Financial CorpBought 17,761 shares on 8/15/2023Ownership: 0.104%View All Insider TransactionsView All Institutional Transactions FGEN Stock - Frequently Asked Questions Should I buy or sell FibroGen stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 sell ratings and 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" FGEN shares. View FGEN analyst ratings or view top-rated stocks. What is FibroGen's stock price forecast for 2023? 6 equities research analysts have issued 12-month price targets for FibroGen's shares. Their FGEN share price forecasts range from $2.00 to $35.00. On average, they anticipate the company's share price to reach $22.00 in the next year. This suggests a possible upside of 2,164.3% from the stock's current price. View analysts price targets for FGEN or view top-rated stocks among Wall Street analysts. How have FGEN shares performed in 2023? FibroGen's stock was trading at $16.02 at the beginning of the year. Since then, FGEN stock has decreased by 93.9% and is now trading at $0.9716. View the best growth stocks for 2023 here. When is FibroGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our FGEN earnings forecast. How were FibroGen's earnings last quarter? FibroGen, Inc. (NASDAQ:FGEN) released its earnings results on Monday, August, 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.07. The biopharmaceutical company had revenue of $44.32 million for the quarter, compared to analyst estimates of $34.17 million. FibroGen had a negative net margin of 246.75% and a negative trailing twelve-month return on equity of 879.75%. What other stocks do shareholders of FibroGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ). When did FibroGen IPO? (FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers. What is FibroGen's stock symbol? FibroGen trades on the NASDAQ under the ticker symbol "FGEN." How do I buy shares of FibroGen? Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is FibroGen's stock price today? One share of FGEN stock can currently be purchased for approximately $0.97. How much money does FibroGen make? FibroGen (NASDAQ:FGEN) has a market capitalization of $95.42 million and generates $140.73 million in revenue each year. The biopharmaceutical company earns $-293,650,000.00 in net income (profit) each year or ($3.39) on an earnings per share basis. How many employees does FibroGen have? The company employs 592 workers across the globe. How can I contact FibroGen? FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The official website for the company is www.fibrogen.com. The biopharmaceutical company can be reached via phone at (415) 978-1200, via email at ir@fibrogen.com, or via fax at 415-978-1902. This page (NASDAQ:FGEN) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.